Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pranlukast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 known ✓ | Q9Y271 | 16/20 | 0.76 |
| ▸ | CYSLTR2 | Q9NS75 | 16/20 | 0.76 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.76 |
| ▸ | PGR | P06401 | 1/20 | 0.76 |
| ▸ | HTR1A | P08908 | 1/20 | 0.76 |
| ▸ | AR | P10275 | 1/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.76 |
| ▸ | DRD1 | P21728 | 1/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.76 |
| ▸ | PDE4A | P27815 | 1/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.76 |
| ▸ | DRD3 | P35462 | 1/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.76 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.76 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.76 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pranlukast SCHEMBL31756724 | 1.00 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| Pranlukast SCHEMBL15546550 | 0.99 | CYSLTR2 (0.75) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| Pranlukast SCHEMBL4467007 | 0.99 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| SCHEMBL6960848 | 0.99 | CYSLTR2 (0.75) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| Pranlukast SCHEMBL100963 | 0.99 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| SCHEMBL8163711 | 0.98 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| Pranlukast SCHEMBL29227539 | 0.96 | CYSLTR2 (0.71) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| SCHEMBL8149103 | 0.92 | CYSLTR2 (0.64) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| SCHEMBL7474226 | 0.91 | CYSLTR2 (0.63) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| Pranlukast SCHEMBL19816814 | 0.91 | CYSLTR2 (0.64) | CYSLTR2CYSLTR1ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12875 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436924-B1 | — | — | None | — | — | US | claimed |
| EP-4676956-A2 | ANTI-STEM CELL FACTOR (SCF) AND ANTI-THYMIC STROMAL LYMPHOPOIETIN (TSLP) ANTIBODIES AND BISPECIFIC CONSTRUCTS | Celldex Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4678659-A1 | MONOCLONAL ANTIBODY PREPARATION TARGETING TSLP | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | claimed |
| US-20260000646-A1 | Inhibition of Oral Microbe Biofilms | THE UNIVERSITY OF TOLEDO (US) | 2026-01-01 | — | — | US | claimed |
| WO-2025264860-A2 | METHODS OF TREATING POST-COVID AIRWAY DISEASE | YALE UNIVERSITY (US) | 2025-12-26 | — | — | WO | claimed |
| WO-2025244529-A1 | DOSING REGIMEN OF AN EGFR BINDING AND/OR COMPLEMENT ACTIVATING ANTIBODY | MERUS N.V. (NL) | 2025-11-27 | — | — | WO | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2025122933-A1 | METHODS FOR THE DETECTION AND TREATMENT OF HEMATOLOGIC MALIGNANCY ASSOCIATED HYPERINFLAMMATION | CHILDRENS HOPSITAL MEDICAL CENTER (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2025122021-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF), THROUGH TARGETING OF S100A9 AND CORRESPONDING DIMER PARTNER AND RECEPTORS | I3S - INSTITUTO DE INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE, ASSOCIAÇÃO (PT) | 2025-06-12 | — | — | WO | claimed |
| WO-2025110687-A1 | PHARMACEUTICAL COMPOSITION COMPRISING BEPOTASTINE AND PRANLUKAST | 대원제약주식회사 | 2025-05-30 | — | — | WO | claimed |
| EP-0834314-A1 | GRANULES CONTAINING PRANLUKAST, PROCESS FOR PRODUCING THE GRANULES, AND METHOD OF LOWERING COHESIVENESS OF PRANLUKAST | ONO PHARMACEUTICAL CO., LTD. (JP) | 1998-04-08 | — | — | EP | claimed |
| EP-0827393-A1 | PHARMACEUTICAL COMPOSITION PREPARED BY ADDITION OF A FLAVOUR VEHICLE TO A MEDICAMENT | SMITHKLINE BEECHAM PLC (GB) | 1998-03-11 | — | — | EP | claimed |
| WO-1998006718-A1 | PROCESS FOR THE PREPARATION OF BENZOPYRAN COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1998-02-19 | — | — | WO | claimed |
| WO-1997028797-A1 | METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSION | MERCK & CO., INC. (US) | 1997-08-14 | — | — | WO | claimed |
| WO-1996037188-A1 | PHARMACEUTICAL COMPOSITION PREPARED BY ADDITION OF A FLAVOUR VEHICLE TO A MEDICAMENT | SMITHKLINE BEECHAM PLC (GB) | 1996-11-28 | — | — | WO | claimed |
| EP-0469477-B1 | Antiallergic combination | HOFFMANN LA ROCHE (CH) | 1995-09-20 | — | — | EP | claimed |
| EP-0641569-A1 | ANTIPRURITIC | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-03-08 | — | — | EP | claimed |
| EP-0173516-B1 | (Fused)benz(thio)amides | ONO PHARMACEUTICAL CO (JP) | 1993-12-01 | — | — | EP | claimed |
| EP-0469477-A1 | Antiallergic combination | F. HOFFMANN-LA ROCHE AG (CH) | 1992-02-05 | — | — | EP | claimed |
| EP-0173516-A2 | (Fused)benz(thio)amides | ONO PHARMACEUTICAL CO., LTD. (JP) | 1986-03-05 | — | — | EP | claimed |